公开(公告)号：WO2022240877A1

公开(公告)日：2022-11-17

申请号：PCT/US2022/028595

申请日：2022-05-10

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： CHIN, Harvey ,  HATSELL, Sarah J. ,  LOB, Heinrich Emil ,  MURPHY, Andrew J. ,  OLSON, William ,  SAOTOME, Kei ,  ZHANG, Bojie

IPC: C07K16/28 ,  A61P7/00 ,  C07K2317/31 ,  C07K2317/76 ,  C07K2317/92

Abstract: Provided herein are monoclonal antibodies that bind to the transmembrane serine protease 6 (TMPRSS6) protein, and methods of use thereof. In various embodiments of the disclosure, the antibodies are fully human antibodies that bind to TMPRSS6. In some embodiments, the antibodies disclosed herein are useful in a method for treating or preventing a disease, disorder or condition associated with TMPRSS6 in humans.

公开(公告)号：WO2021163170A1

公开(公告)日：2021-08-19

申请号：PCT/US2021/017427

申请日：2021-02-10

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： IDONE, Vincent J. ,  HATSELL, Sarah J. ,  ECONOMIDES, Aris N.

IPC: C07K16/28 ,  A61K39/395 ,  A61P19/08 ,  A61K39/00

Abstract: The present invention provides monoclonal antibodies that bind to the Activin A type I receptor (ACVR1) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to ACVR1. In some embodiments, the antibodies of the invention are useful for inhibiting ACVR1-mediated bone morphogenetic protein (BMP) signal transduction, thus providing a means of treating or preventing a disease, disorder or condition associated with ACVR1.

公开(公告)号：WO2020251924A1

公开(公告)日：2020-12-17

申请号：PCT/US2020/036771

申请日：2020-06-09

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： HATSELL, Sarah J. ,  IDONE, Vincent J. ,  MURPHY, Andrew J.

IPC: C07K16/22 ,  A61P7/06 ,  A61K39/395

Abstract: The present invention provides antibodies that bind to BMP6, and methods of use. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to BMP6. The antibodies of the invention are useful for inhibiting binding of BMP6 to the hemojuvelin receptor, thereby down-regulating transcription and expression of hepcidin, thus providing a means of preventing or treating an iron-deficiency anemia or an iron-deficiency related disorder. In some embodiments, the antibodies of the present invention are used in treating at least one symptom or complication of an iron-deficiency anemia or an iron-deficiency related disorder.

公开(公告)号：WO2019241350A1

公开(公告)日：2019-12-19

申请号：PCT/US2019/036719

申请日：2019-06-12

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： HATSELL, Sarah J. ,  ECONOMIDES, Aris N. ,  SCHOENHERR, Christopher ,  IDONE, Vincent J.

IPC: A01K67/027

Abstract: A genetically modified rodent is provided that comprises a modified Acvr1 gene that comprises a conditional altered exon 7 encoding R258G in antisense orientation, flanked by site-specific recombinase recognition sites, wherein the altered exon is inverted to sense orientation upon action of a recombinase, resulting in ectopic bone formation.

公开(公告)号：WO2016176341A1

公开(公告)日：2016-11-03

申请号：PCT/US2016/029585

申请日：2016-04-27

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： HATSELL, Sarah J. ,  ECONOMIDES, Aris N. ,  IDONE, Vincent J.

IPC: C07K16/22

CPC classification number: C07K16/22 ,  A61K31/138 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/76

Abstract: Methods for treating Fibrodysplasia Ossificans Progressiva (FOP) are provided in which a subject having FOP is administered an effective regime of an antibody against Activin B, BMP9 or BMP10.

Abstract translation: 提供治疗纤维发育不良症的方法Progressive（FOP），其中具有FOP的受试者施用针对活化素B，BMP9或BMP10的抗体的有效方案。